CommercialCoverageMedium impact
Endolymphatic Hydrops (Meniere's Disease) Tests (CPB 0571, reviewed 2026-09-01)
Aetna·ENT (Ear, Nose & Throat), Audiology, Neurology·Medical Policy
We identified it
Oct 1, 2026
Summary
Aetna updated its policy on Meniere's disease diagnostic testing (CPB 0571), establishing that dehydration testing with osmotic diuretics is covered only for atypical presentations, while designating multiple tests as experimental/investigational including genetic testing, gadolinium MRI, VEMP, multi-frequency tympanometry, and inner ear antibody testing. Billing teams must immediately deny claims for the experimental tests listed and require documentation of atypical presentation before covering dehydration testing.
Action Required
Immediately: Billing team must update claim submission rules in billing software to deny or request prior authorization for the following CPT/HCPCS codes when billed for Meniere's disease or endolymphatic hydrops diagnosis: 81406 (genetic testing), 92517/92518/92519 (VEMP testing), 92550/92567 (multi-frequency tympanometry), 92584 (electrocochleography), and A9579 (gadolinium contrast). Genetic testing codes KCNE1, KCNE3, SIK1, SLC8A1, and SLC26A4 should be flagged as non-covered. For dehydration testing (no specific CPT code listed), require provider documentation of atypical presentation in medical record before claim approval; claims lacking this documentation should be denied. Update claim denial templates to reference CPB 0571 and specify experimental/investigational status. Train billing staff on which tests are non-covered versus covered-with-conditions. Failure to implement will result in improper claim payments and audit exposure.